Objective: To investigate the effect of adjuvant therapy on the treatment of carcinoma of the body and tail of pancreas.
Methods: The clinical data of 137 patients with carcinoma of the body and tail of pancreas, 91 males and 46 females, aged 58.9 (24 - 76), of which 38 underwent radical resection, 24 underwent palliative resection, and 75 did not undergo resection, and 58 of which underwent adjuvant therapy, were analyzed.
Results: The overall 3-year survival rate was 10.7% for the whole group, 27.3% for the radical resection group, 4.2% for the palliative resection, and 4.5% for the no resection group. The median survival time (MST) was 8 months for the whole group, 15 months for the radical resection group, 8 months for the palliative resection group, and 6 months for the no resection group. The 3-year survival rate was 13.9% for the patients undergoing adjuvant therapy and 7.2% for those without adjuvant therapy, and the MST was 11 months for those undergoing adjuvant therapy, and 5 months for those without adjuvant therapy. Intra-arterial therapy and radiation therapy were protective factors for those whose cancerous tissues were not radically resected (OR = 1.56, 95% CI: 1.04 - 2.35, P = 0.033).
Conclusion: Adjuvant therapy significantly improves the survival of the patients with pancreatic carcinoma of the body and tail. The clinical effect of intra-arterial therapy is better than those of radiation therapy and chemotherapy.